| CAS NO: | 59-14-3 |
| 规格: | ≥98% |
| 包装 | 价格(元) |
| 100mg | 电议 |
| 250mg | 电议 |
| 500mg | 电议 |
| 1g | 电议 |
| 2g | 电议 |
| 5g | 电议 |
| Molecular Weight (MW) | 307.1 |
|---|---|
| Formula | C9H11BrN2O5 |
| CAS No. | 59-14-3 |
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Solubility (In vitro) | DMSO: 61 mg/mL (198.6 mM) |
| Water: <1 mg/mL | |
| Ethanol: 3 mg/mL (9.8 mM) | |
| Other info | Chemical Name: 5-Bromo-2'-deoxyuridine InChi Key: WOVKYSAHUYNSMH-RRKCRQDMSA-N InChi Code: InChI=1S/C9H11BrN2O5/c10-4-2-12(9(16)11-8(4)15)7-1-5(14)6(3-13)17-7/h2,5-7,13-14H,1,3H2,(H,11,15,16)/t5-,6+,7+/m0/s1 SMILES Code: OC[C@@H]1[C@H](C[C@H](N2C(NC(C(Br)=C2)=O)=O)O1)O |
| Synonyms | BrdU; Broxuridine; 5-Bromo-2'-deoxyuridine; BUdR |
| In Vitro | In vitro activity: In RG2 rat glioma cells, Bromodeoxyuridine induces a progressive, dose-responsive suppression of cancer cell line and cancer stem cell population expansion. In H9 cells and BJ fibroblasts, Bromodeoxyuridine alters the cell cycle profile. BrdU is stably integrated into the DNA, and thus can be used in assessment of cell proliferation and other cell procession. Cell Assay: Cultures are initially plated at 2000 cells/cm2 and are quantified with a Z2 Coulter Counter. RG2 rat glioma cells are treated once with 0, 1, 10, or 50 μM BrdU for 24 hours, and cumulative growth curves were obtained over 18 days. Control and treated cells are quantified and replated at equal densities on days 5, 12, and 18 after treatment. |
|---|---|
| In Vivo | In rat glioma RG2 tumor model, Bromodeoxyuridine (300 mg/kg, i.p. or 0.8 mg/ml, p.o.) significantly slows tumor progression. |
| Animal model | Rat glioma RG2 tumor model |
| Formulation & Dosage | 300 mg/kg, i.p. or 0.8 mg/ml, p.o. |
| References | Neoplasia. 2008 Aug;10(8):804-16; Curr Protoc Cytom. 2007 Apr;Chapter 7:Unit7.31. |
m.cnreagent.com